A clinical study of bevacizumab to analyze a correlation of efficacy and the VEGF-related gene cluster for Patients with Advanced Non- Squamous Non-Small Cell Lung Cancer -KTOSG1003
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000007630
- Lead Sponsor
- Department of Respiratory Medicine, Kumamoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
(1)CNS metastasis. (2)History of treatment for brain metastasis. (3)History of active double cancer. (4)History of hemoptysis or hemosputum. (5)Evidence of bleeding diathesis or coagulopathy. (6)With great vessel invasion or cavity in tumor. (7)Radiotherapy for thoracic lesions. (8)History of severe heart disease. (9)Superior vena cava syndrome. (10)Spinal cord compression (11)Current or previous history (within the last 1 year) of symptomatic cerebrovascular disease. (12)Non-healing bone fracture and wound. (13)Active infectious disease in need of intravenous administration of anti-bacterial, anti-fungal, or anti-viral drugs. (14)Plan of the operation. (15)Uncontrollable thrombosis. (16)Uncontrollable gastrointestinal ulceration. (17)Current or previous(within the last 1 year)history of GI perforation. (18)Uncontrollable systemic disease (hyper tension or diabetes mellitus). (19)Severe cardiac disease. (20)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray. (21)Peripheral neuropathy > Grade2. (22)With a history of drug sensitivity. (23)History of bevacizumab treatment in the past. (24)History of pregnancy or lactation. (25)No intention to practice birth control. (26)Registration to other trial. (27)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method